Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer — Stella

Home/Ovarian Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Ovarian Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Key details

Phase

Early testing

Sponsor

Tongji Hospital

Collaborators

Qilu Hospital of Shandong University, People's Hospital of Quzhou

Enrollment target

~30 participants

Started

February 2023

Primary completion

June 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Sex

Female only

Last updated August 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.